Vera Therapeutics Inc Asset Resilience Ratio
Vera Therapeutics Inc asset resilience ratio. Vera Therapeutics Inc (VERA) has an Asset Resilience Ratio of 77.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vera Therapeutics Inc (VERA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vera Therapeutics Inc (2019–2025)
Asset resilience ratio of Vera Therapeutics Inc from 2019 to 2025. This chart shows how Vera Therapeutics Inc's Asset Resilience Ratio has changed over time. Read VERA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vera Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VERA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $482.41 Million | 77.59% |
| Total Liquid Assets | $482.41 Million | 77.59% |
Asset Resilience Insights
- Very High Liquidity: Vera Therapeutics Inc maintains exceptional liquid asset reserves at 77.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vera Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Vera Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Vera Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Vera Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Vera Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.98% | $359.86 Million | $734.73 Million | -34.63pp |
| 2024-12-31 | 83.61% | $548.21 Million | $655.68 Million | +18.08pp |
| 2023-12-31 | 65.53% | $115.03 Million | $175.55 Million | +11.36pp |
| 2022-12-31 | 54.17% | $71.19 Million | $131.44 Million | +53.13pp |
| 2021-12-31 | 1.04% | $867.00K | $83.75 Million | +1.04pp |
| 2020-12-31 | 0.00% | $86.00 | $54.55 Million | 0.00pp |
| 2019-12-31 | 0.00% | $34.00 | $5.38 Million | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more